___________________________________________________________

For Clinical Trial information click here
Or contact the name below each study.

Psoriasis Studies

Disulfiram study
Subjects: Healthy 18-60 yo with psoriasis BSA =3%, willing/able to completely abstain from alcohol throughout the study.
Study: Open-label pilot study of oral medication. Visits every 2 weeks for a total duration of ~4 months.
Contact: Mary Ann Smith ( MaryAnn.Smith@UHhospitals.org, 216-844-7164) or Jennifer Bahner ( Jennifer.Bahner@UHhospitals.org, 216-844-1913)

Cyclosporine study
Subjects: Healthy 18-70 yo with psoriasis BSA >10%, never been treated with cyclosporine.
Study: Multi-stage, randomized, double-blind study where all patients are treated initially with oral cyclosporine. The longest duration of cyclosporine treatment is 7 months. Visits every 2 weeks for up to 10 months, then every 6 months for 2 additional years (during which time patients can use other treatments outside of study).
Contact: Mary Ann Smith ( MaryAnn.Smith@UHhospitals.org, 216-844-7164) or Jennifer Bahner (Jennifer.Bahner@UHhospitals.org, 216-844-1913)

Turbo UVB Study
Subjects: Healthy 18-80 yo with at least 2 psoriasis plagues.
Study: Translational study to determine the optimal timing and dosing for UVB and topical treatment of psoriasis utilizing Imiquimod and Clobetasol. Five visits over approximately 5 weeks.
Contact:

Etanercept Study
Subjects: Healthy 18-80 yo with psoriasis BSA =3%
Study: Randomized, double-blinded study to determine if etanercept changes the skin’s immune response to sunlight, participants self-inject etanercept or placebo for 8 weeks. Then sensitivity of skin is tested with DNCB after UV irradiation. Total of 8 visits over 11 weeks.
Contact: Christi Malbasa (Christi.Malbasa@UHhospitals.org, 216-844-7834)

Pc4 Study
Subjects: Healthy 18+ yo with at least 3 plaques
Study: Pilot study of Pc4 PDT. All subjects will receive treatment with 3 follow-up visits over 2 weeks.
Contact: Christi Malbasa (Christi.Malbasa@UHhospitals.org, 216-844-7834)

Psoriasis Blood and Skin
Subjects: Healthy adults with psoriasis off therapy; may be on topicals for blood
Study: Blood draw and/or punch biopsies, one visit (possibility for more if subject willing/able)
Contact: Christi Malbasa (Christi.Malbasa@UHhospitals.org, 216-844-7834)

Prevalence Study
Subjects: Psoriasis patients 18+ yo as well as normal controls
Study: Evaluates cardiovascular disease risk profile in psoriasis pts and normal controls. Consent and baseline study visit, with the possibility of one additional f/u visit for both psoriasis patients and controls approx. 3-6 months later. Study visit includes vascular ultrasounds, coronary artery CT, and fasting blood draw.
Contact: Doug Kast (Doug.Kast@UHhospitals.org, 216-844-5728) or Rivka Feig (Rivka.Feig@UHhospitals.org, 216-983-5762)

Database Study
Subjects: Patients with psoriasis 18 and over
Study: Questionnaire-based study with physical exam on the f/u visit; Two visits (consent and f/u)
Contact: Ivan Grozdev (Ivan.Grozdev@UHhospitals.org, 216-844-5728)

Vitamin D Study
Subjects: Patients with psoriasis 18 and over
Study: One visit – blood draw for the Vitamin D levels, exam, and history
Contact: Ivan Grozdev (Ivan.Grozdev@UHhospitals.org, 216-844-5728)

OTHER STUDIES

Remicade for Pyoderma Gangrenosum
Subjects: 18-75 yo with =3 month history of pyoderma gangrenosum and a diagnosis of inflammatory bowel disease (Crohn's or ulcerative colitis) who has never received Remicade for PG and has active PG despite a history of at least one standard therapy for PG.
Study: Open-label study of IV Remicade. Visits every 2 weeks initially, total duration ~6 months.
Contact: Mary Ann Smith (MaryAnn.Smith@UHhospitals.org, 216-844-7164) or Jennifer Bahner (Jennifer.Bahner@UHhospitals.org, 216-844-1913)

Apremilast for Prurigo Nodularis
Subjects: Healthy =18 yo with =6-month history of prurigo nodularis who has failed 1 standard therapy (e.g. topical steroids).
Study: Open-label pilot study of oral medication. Visits every 1-2 weeks, total duration ~4 months
Contact: Mary Ann Smith (MaryAnn.Smith@UHhospitals.org, 216-844-7164) or Jennifer Bahner (Jennifer.Bahner@UHhospitals.org, 216-844-1913)

Eczema Blood and Skin
Subjects: Healthy adults with eczema
Study: Blood draw and/or punch biopsies, one visit with possibility for more
Contact: Christi Malbasa (Christi.Malbasa@UHhospitals.org, 216-844-7834)

Green Tea for Facial Erythema
Subjects: healthy adults with facial redness due to rosacea, aging, or photo-aging
Study: BID facial cream application for 6 weeks. Total of 5 visits over 8 weeks.
Contact: Christi Malbasa (Christi.Malbasa@UHhospitals.org, 216-844-7834)

CTCL STUDIES

Enzastaurin for CTCL
Subjects: =18 years of age; CTCL or sezary syndrome Stage IB to IVB disease at screening; recurrent or refractory disease after at least 1 prior therapy, 1 of which must be either bexarotene or vorinostat; visits approximately every 4 weeks after baseline visit;
Study: Open-label study of oral enzastaurin in patients with relapsed cutaneous t-cell lymphoma
Contact: Sean Carlson (sean.carlson@UHhospitals.org, 216-844-5899)

O6BG/BCNU for CTCL
Subjects: age >18 years; diagnosis of CTCL stages IA-IIA; must have failed at least on conventional treatment for CTCL other than topical corticosteroids (e.g. phototherapy, bexarotene, photopheresis, etc.); weekly visits
Study: Trial of O6Benzylguanine and topical carmustine in the treatment of refractory early-stage CTCL
Contact: Sean Carlson (sean.carlson@UHhospitals.org, 216-844-5899)

Forodesine for CTCL
Subjects: age ?18 years; diagnosis of CTCL or sezary syndrome, stages IB, IIA, IIB, III, or IVA at the screening visit; have persistent, progressive, or recurrent disease during or following treatment with at least three forms of systemic therapy, one of which must have been oral bexarotene, unless treatment with oral was not tolerated or was medically contraindicated; visits approximately every 2 weeks
Study: oral forodesine (BCX1777) in the treatment of CTCL
Contact: Sean Carlson (sean.carlson@UHhospitals.org, 216-844-5899)

 

 

CENTER NEWS

First Ever Psoriasis Legislation Introduced in Congress
National Psoriasis Foundation to ask for support of bill on Capitol Hill Day

University Hospitals
Receives $5 Million
Largest Dermatology Gift
in the U.S.

More news >>

RELATED LINKS

National Psoriasis Foundation
Non-profit organization dedicated to educating, serving and empowering people with psoriasis and psoriatic arthritis.

National Institutes of Health (NIH)
The primary Federal agency for conducting and supporting medical research.

Medline Plus
Service provided by the National Library of Medicine, the National Institutes of Health (NIH) and other government agencies and health-related organizations.